• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2020 Agency for Healthcare Research and Quality (AHRQ) Treatment of depression in children and adolescents
2020 Agency for Healthcare Research and Quality (AHRQ) Treatments for acute pain: a systematic review
2020 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Proposal for the organization of bariatric medicine for the territories of the integrated university health and social services network of Laval University]
2020 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Exploratory evaluation of the relevance, use, and impacts of teleconsultations]
2020 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Field evaluation of the implementation of video teleconsultations during the COVID-19 pandemic at the Quebec Heart and Lung Institute]
2020 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Literature review on efficacy and safety of ultraviolet light and ozone for surface disinfection (Update)]
2020 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Safety and efficacy of Thai massage as a therapeutic intervention in clinical pathologies]
2020 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Implantable automatic defibrillator for primary prevention of sudden cardiac death in Spain: efficacy, safety, and efficiency]
2020 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of active spiritual healing]
2020 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Fall-safe assist. Portable device for falls prevention]
2020 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficiency of 3D reconstruction in maxillofacial surgery]
2020 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the clinical effectiveness and safety of primary shoulder arthroplasty]
2020 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Halcyon intensity-modulated beam conformal image-guided volumetric radiotherapy system for oncology treatment]
2020 The Regional Health Technology Assessment Centre (HTA-centrum) Does headgear type used by the operating room staff affect postoperative surgical site infection rate?
2020 The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy of transcutaneous vagus nerve stimulation as treatment for patients with depression
2020 The Regional Health Technology Assessment Centre (HTA-centrum) Is there an association between the proportion of registered nurses (skill-mix) in the hospital health care team, and patient mortality or risk for falls or pressure ulcers?
2020 The Regional Health Technology Assessment Centre (HTA-centrum) Safety and effectiveness of outpatient compared with inpatient induction of labour in singleton uncomplicated pregnancies
2020 The Regional Health Technology Assessment Centre (HTA-centrum) Magnetic resonance image-guided radiotherapy in patients with cancer in thorax, abdomen, pelvis or head and neck
2020 The Regional Health Technology Assessment Centre (HTA-centrum) Anti-inflammatory, antibiotic and immunomodulatory treatment in children with symptoms corresponding to the research condition PANS (Pediatric Acute-onset Neuropsychiatric Syndrome)
2020 The Regional Health Technology Assessment Centre (HTA-centrum) Effectiveness of laminar versus turbulent airflow in operating theaters, with regard to risk for postoperative surgical infections
2020 The Regional Health Technology Assessment Centre (HTA-centrum) Update: Chlorhexidine wash prior to clean surgical procedures
2020 The Regional Health Technology Assessment Centre (HTA-centrum) Nature-based rehabilitation for patients with longstanding stress-related disorders – an updated report
2020 The Regional Health Technology Assessment Centre (HTA-centrum) Induction of labour at 41 or 42 weeks of gestation
2020 National Institute for Health and Care Excellence (NICE) Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. NICE technology appraisal guidance 617
2020 National Institute for Health and Care Excellence (NICE) Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 618
2020 National Institute for Health and Care Excellence (NICE) Sotagliflozin with insulin for treating type 1 diabetes. NICE technology appraisal guidance 622
2020 National Institute for Health and Care Excellence (NICE) Patiromer for treating hyperkalaemia. NICE technology appraisal guidance 623
2020 National Institute for Health and Care Excellence (NICE) Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 624
2020 National Institute for Health and Care Excellence (NICE) Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal). NICE technology appraisal guidance 625
2020 National Institute for Health and Care Excellence (NICE) Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. NICE technology appraisal guidance 626
2020 National Institute for Health and Care Excellence (NICE) Lenalidomide with rituximab for previously treated follicular lymphoma. NICE technology appraisal guidance 627
2020 National Institute for Health and Care Excellence (NICE) Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 628
2020 National Institute for Health and Care Excellence (NICE) Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab. NICE technology appraisal guidance 629
2020 National Institute for Health and Care Excellence (NICE) Larotrectinib for treating NTRK fusion-positive solid tumours. NICE technology appraisal guidance 630
2020 National Institute for Health and Care Excellence (NICE) Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. NICE technology appraisal guidance 632
2020 National Institute for Health and Care Excellence (NICE) Ustekinumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 633
2020 National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 634
2020 National Institute for Health and Care Excellence (NICE) Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 635
2020 National Institute for Health and Care Excellence (NICE) Eculizumab for treating refractory myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 636
2020 National Institute for Health and Care Excellence (NICE) Ranibizumab for treating diabetic retinopathy (terminated appraisal). NICE technology appraisal guidance 637
2020 National Institute for Health and Care Excellence (NICE) Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 638
2020 National Institute for Health and Care Excellence (NICE) Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. NICE technology appraisal guidance 639
2020 National Institute for Health and Care Excellence (NICE) Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant. NICE technology appraisal guidance 640
2020 National Institute for Health and Care Excellence (NICE) Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma. NICE technology appraisal guidance 641
2020 National Institute for Health and Care Excellence (NICE) Gilteritinib for treating relapsed or refractory acute myeloid leukaemia. NICE technology appraisal guidance 642
2020 National Institute for Health and Care Excellence (NICE) Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 643
2020 National Institute for Health and Care Excellence (NICE) Entrectinib for treating NTRK fusion-positive solid tumours. NICE technology appraisal guidance 644
2020 National Institute for Health and Care Excellence (NICE) Avelumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 645
2020 National Institute for Health and Care Excellence (NICE) Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 646
2020 National Institute for Health and Care Excellence (NICE) Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal). NICE technology appraisal guidance 647
2020 National Institute for Health and Care Excellence (NICE) Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal). NICE technology appraisal guidance 648
2020 National Institute for Health and Care Excellence (NICE) Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 649
2020 National Institute for Health and Care Excellence (NICE) Pembrolizumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 650
2020 National Institute for Health and Care Excellence (NICE) Naldemedine for treating opioid-induced constipation. NICE technology appraisal guidance 651
2020 National Institute for Health and Care Excellence (NICE) Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 653
2020 National Institute for Health and Care Excellence (NICE) Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 654
2020 National Institute for Health and Care Excellence (NICE) Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 655
2020 National Institute for Health and Care Excellence (NICE) Siponimod for treating secondary progressive multiple sclerosis. NICE technology appraisal guidance 656
2020 National Institute for Health and Care Excellence (NICE) Carfilzomib for previously treated multiple myeloma. NICE technology appraisal guidance 657
2020 National Institute for Health and Care Excellence (NICE) Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 658
2020 National Institute for Health and Care Excellence (NICE) Galcanezumab for preventing migraine. NICE technology appraisal guidance 659
2020 National Institute for Health and Care Excellence (NICE) Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 660
2020 National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. NICE technology appraisal guidance 661
2020 National Institute for Health and Care Excellence (NICE) Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 662
2020 National Institute for Health and Care Excellence (NICE) Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 663
2020 National Institute for Health and Care Excellence (NICE) Liraglutide for managing overweight and obesity. NICE technology appraisal guidance 664
2020 National Institute for Health and Care Excellence (NICE) Upadacitinib for treating severe rheumatoid arthritis. NICE technology appraisal guidance 665
2020 National Institute for Health and Care Excellence (NICE) Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma. NICE technology appraisal guidance 666
2020 National Institute for Health and Care Excellence (NICE) Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura. NICE technology appraisal guidance 667
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anxiety disorders: does the complementary use of eye movement desensitization and reprocessing (EMDR) therapy as a psychotherapeutic approach lead to better results?]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Testicular cancer: does regular screening for men from the age of 16 lead to better treatment outcomes?]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cervical spine syndrome: the impact of the duration and frequency of physiotherapy on treatment success]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Seasonal affective disorder: do non-drug interventions such as light and vitamin therapy lead to better results?]
2020 National Institute for Health and Care Excellence (NICE) Swallowable gastric balloon capsule for weight loss. NICE interventional procedures guidance 684
2020 National Institute for Health and Care Excellence (NICE) Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis. NICE interventional procedures guidance 681
2020 National Institute for Health and Care Excellence (NICE) Balloon cryoablation for Barrett's oesophagus. NICE interventional procedures guidance 682
2020 National Institute for Health and Care Excellence (NICE) Balloon cryoablation for squamous dysplasia of the oesophagus. NICE interventional procedures guidance 683
2020 National Institute for Health and Care Excellence (NICE) Transcranial magnetic stimulation for auditory hallucinations. NICE interventional procedures guidance 680
2020 National Institute for Health and Care Excellence (NICE) Deep brain stimulation for refractory epilepsy in adults. NICE interventional procedures guidance 678
2020 National Institute for Health and Care Excellence (NICE) Implanted vagus nerve stimulation for treatment-resistant depression. NICE interventional procedures guidance 679
2020 National Institute for Health and Care Excellence (NICE) Transcranial magnetic stimulation for obsessive-compulsive disorder. NICE interventional procedures guidance 676
2020 National Institute for Health and Care Excellence (NICE) Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. NICE interventional procedures guidance 677
2020 National Institute for Health and Care Excellence (NICE) Artificial iris insertion for acquired aniridia. NICE interventional procedures guidance 674
2020 National Institute for Health and Care Excellence (NICE) Artificial iris insertion for congenital aniridia. NICE interventional procedures guidance 675
2020 National Institute for Health and Care Excellence (NICE) Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention. NICE interventional procedures guidance 673
2020 National Institute for Health and Care Excellence (NICE) Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse. NICE interventional procedures guidance 669
2020 National Institute for Health and Care Excellence (NICE) Cyanoacrylate glue occlusion for varicose veins. NICE interventional procedures guidance 670
2020 National Institute for Health and Care Excellence (NICE) MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy. NICE interventional procedures guidance 671
2020 National Institute for Health and Care Excellence (NICE) Selective internal radiation therapy for unresectable colorectal metastases in the liver. NICE interventional procedures guidance 672
2020 National Institute for Health and Care Excellence (NICE) Fetoscopic prenatal repair for open neural tube defects in the fetus. NICE interventional procedures guidance 667
2020 National Institute for Health and Care Excellence (NICE) Open prenatal repair for open neural tube defects in the fetus. NICE interventional procedures guidance 668
2020 National Institute for Health and Care Excellence (NICE) Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues. NICE interventional procedures guidance 666
2020 HTA South [Exercise test in the investigation of suspected chronic coronary syndrome: a comparison with imaging and other functional tests]
2020 HTA South [The use of hydrogel spacer in radiotherapy of prostate cancer]
2020 National Institute for Health and Care Excellence (NICE) Zio XT for detecting cardiac arrhythmias. NICE medical technologies guidance 52
2020 National Institute for Health and Care Excellence (NICE) SEM Scanner 200 for preventing pressure ulcers. NICE medical technologies guidance 51
2020 National Institute for Health and Care Excellence (NICE) Axonics sacral neuromodulation system for treating refractory overactive bladder. NICE medical technologies guidance 50
2020 National Institute for Health and Care Excellence (NICE) Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. NICE medical technologies guidance 49
2020 National Institute for Health and Care Excellence (NICE) PneuX to prevent ventilator-associated pneumonia. NICE medical technologies guidance 48
2020 National Institute for Health and Care Excellence (NICE) Episcissors-60 for mediolateral episiotomy. NICE medical technologies guidance 47